Carl Sailer

All filings by Carl Sailer on record concern Acurx Pharmaceuticals, Inc., in the capacity of board member. The record holds 5 filings, for trades running from 29 June 2021 to 6 January 2025.

No open-market sale appears; the market trades are 4 purchases worth €183k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 option exercise. In 2025 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €44k. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 8 January 2025 with an open-market purchase (€24k) in Acurx Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.